User profiles for "author:Aude Desnoyer"
 | Aude DesnoyerAssistance Publique Hôpitaux de Paris Verified email at aphp.fr Cited by 1085 |
[HTML][HTML] Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies
A Desnoyer, S Broutin, J Delahousse, C Maritaz… - European Journal of …, 2020 - Elsevier
Immune checkpoint inhibitors are monoclonal antibodies (mAbs) directed against negative
immunologic regulators that are used to restore the immune response against cancer …
immunologic regulators that are used to restore the immune response against cancer …
Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients
Background The development of immune checkpoint blockade (ICB) has revolutionized the
clinical outcome of renal cell carcinoma (RCC). Nevertheless, improvement of durability and …
clinical outcome of renal cell carcinoma (RCC). Nevertheless, improvement of durability and …
[HTML][HTML] Integrating circulating biomarkers in the immune checkpoint inhibitor treatment in lung cancer
B Duchemann, J Remon, M Naigeon, L Mezquita… - Cancers, 2020 - mdpi.com
Simple Summary Immune checkpoint inhibitors (ICI) are now a cornerstone of treatment for
non-small cell lung cancer (NSCLC). Despite reporting tremendous results for some …
non-small cell lung cancer (NSCLC). Despite reporting tremendous results for some …
[HTML][HTML] Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug …
A Paci, A Desnoyer, J Delahousse, L Blondel… - European Journal of …, 2020 - Elsevier
More than 25 therapeutic monoclonal antibodies (mAbs) used in oncology have been
approved since 1997. Their nature has been largely modified through the last 20 years, from …
approved since 1997. Their nature has been largely modified through the last 20 years, from …
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C
A Desnoyer, D Pospai, MP Lê, A Gervais… - Journal of …, 2016 - Elsevier
Background & Aims Hepatitis C virus (HCV) infection is an independent risk factor for
chronic kidney disease and leads to faster liver disease progression in patients requiring …
chronic kidney disease and leads to faster liver disease progression in patients requiring …
Circulating T-cell immunosenescence in patients with advanced non–small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based …
Abstract Purpose: CD28, CD57, and KLRG1 have been previously identified as markers of T-
cell immunosenescence. The impact of immunosenescence on anti-PD (L)-1 (ICI) or …
cell immunosenescence. The impact of immunosenescence on anti-PD (L)-1 (ICI) or …
[HTML][HTML] CD8+ PD-1+ to CD4+ PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L) 1 blockers
B Duchemann, M Naigeon, E Auclin… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Programmed cell death protein-1 (PD-1) expression has been associated with
activation and exhaustion of both the CD4 and CD8 populations in advanced non-small cell …
activation and exhaustion of both the CD4 and CD8 populations in advanced non-small cell …
PIM-Check: development of an international prescription-screening checklist designed by a Delphi method for internal medicine patients
A Desnoyer, AL Blanc, V Pourcher, M Besson… - BMJ open, 2017 - bmjopen.bmj.com
Objectives Potentially inappropriate medication (PIM) occurs frequently and is a well-known
risk factor for adverse drug events, but its incidence is underestimated in internal medicine …
risk factor for adverse drug events, but its incidence is underestimated in internal medicine …
The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers
C Freitas, A Desnoyer, F Meuris, F Bachelerie… - Cytokine & growth factor …, 2014 - Elsevier
Recent studies have highlighted the importance of understanding the molecular
determinants of CXCL12-mediated effects in cancers. Once previously thought to interact …
determinants of CXCL12-mediated effects in cancers. Once previously thought to interact …
DUSP4-mediated accelerated T-cell senescence in idiopathic CD4 lymphopenia
A Bignon, A Régent, L Klipfel… - Blood, The Journal …, 2015 - ashpublications.org
Idiopathic CD4 lymphopenia (ICL) is a rare heterogeneous immunological syndrome of
unclear etiology. ICL predisposes patients to severe opportunistic infections and frequently …
unclear etiology. ICL predisposes patients to severe opportunistic infections and frequently …